 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
International News GeoVax Partners With French FirmJuly 25, 2008 On Thursday, Atlanta-based GeoVax Labs Inc. announced a new partnering agreement under which a component of its candidate HIV vaccine will be manufactured by the French firm Vivalis. GeoVax has reported progress toward Phase II preventive clinical human trials of its vaccine and plans to move into therapeutic human trials this fall, said Robert McNally, its president and CEO. The Phase II trial will be conducted by the National Institutes of Health with the support of the HIV Vaccine Trials Network. It will involve 225 healthy volunteers from the United States and South America. Atlanta Journal-Constitution 07.25.2008; Bill Hendrick  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Site Policies | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
